Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has earned an average rating of “Buy” from the twenty-seven research firms that are covering the firm, MarketBeat reports. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $154.45.

A number of equities analysts have commented on ALXN shares. TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, November 10th. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Royal Bank Of Canada lifted their price target on Alexion Pharmaceuticals to $166.00 in a research note on Tuesday, October 24th. Stifel Nicolaus decreased their price target on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research note on Tuesday, October 24th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $170.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, October 23rd.

COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/21/alexion-pharmaceuticals-inc-alxn-given-consensus-recommendation-of-buy-by-analysts.html.

Alexion Pharmaceuticals (NASDAQ ALXN) opened at $108.49 on Tuesday. The firm has a market capitalization of $24,769.42, a PE ratio of 22.67, a P/E/G ratio of 1.21 and a beta of 1.22. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period last year, the firm posted $1.23 EPS. research analysts anticipate that Alexion Pharmaceuticals will post 4.81 earnings per share for the current year.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares in the company, valued at $799,038.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Julie O’neill sold 11,160 shares of Alexion Pharmaceuticals stock in a transaction on Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the transaction, the executive vice president now owns 26,704 shares of the company’s stock, valued at approximately $3,738,560. The disclosure for this sale can be found here. Insiders have sold 16,490 shares of company stock worth $2,337,251 over the last 90 days. 4.35% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the business. Commerzbank Aktiengesellschaft FI raised its stake in Alexion Pharmaceuticals by 151.5% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock valued at $16,145,000 after buying an additional 79,943 shares during the last quarter. HPM Partners LLC raised its stake in Alexion Pharmaceuticals by 267.2% during the second quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 4,861 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in Alexion Pharmaceuticals by 4,509.0% during the third quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after buying an additional 864,967 shares during the last quarter. Principal Financial Group Inc. raised its stake in Alexion Pharmaceuticals by 1.2% during the second quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock valued at $40,823,000 after buying an additional 4,115 shares during the last quarter. Finally, IFC Holdings Incorporated FL purchased a new position in Alexion Pharmaceuticals during the third quarter valued at $861,000. Institutional investors and hedge funds own 95.80% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.